Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 99

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 6
Chunk 99
---
 to iss...  

  reviewing and approving all proposed related party transactions, as defined in Item 404 of Regulation S-K under the Securities Act;  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  discussing the annual audited financial statements with management and the independent registered public accounting firm;  

  reviewing policies with respect to risk assessment and risk management;  

  reviewing the adequacy and effectiveness of the Company’s accounting and internal control policies and procedures and any special steps taken to monitor and control major financial risk exposures;  

  periodically reviewing and reassessing the adequacy of the committee charter;  

  approving annual audit plans, and undertaking an annual performance evaluation of the internal audit function;  

  establishing and overseeing procedures for the handling of complaints and whistleblowing;  

  meeting separately and periodically with management, the internal auditors and the independent registered public accounting firm;  

  monitoring compliance with the Company’s code of business conduct and ethics, including reviewing the adequacy and effectiveness of its procedures to ensure proper compliance;  

  reporting periodically to the Board; and  

  such other matters that are specifically delegated to the Company’s Audit Committee by the Board from time to time.  

A copy of
the audit committee’s current charter is available at our corporate website at www. newgenivf. com.

Compensation Committee. Our Compensation Committee (“ Compensation Committee”) consists of Mr. Wing Fung Alfred Siu and Ms. Hei Yue Tina Fong. The
Chairman of the Compensation Committee is Mr. Siu. The Company has determined that Mr. Foo satisfies the “independence” requirements
of Rule 5605(c)(2) of the Nasdaq Stock Market Listing Rules. Upon Mr. Foo’s resignation on April 4, 2025 from all his
positions, Ms Florianna Anne Chi Wan Chan, having satisfied the requirements as mentioned, was appointed to the Committee on April 15,2025.
The Compensation Committee assists the Board in reviewing and approving compensation structure, including all forms of compensation relating
to the Company’s directors and executive officers. The Company’s Chief Executive Officer may not be present at any committee
meeting during which their compensation is deliberated upon. The Compensation Committee is responsible for, among other things:

  reviewing and evaluating the Company’s executive compensation and benefits policies generally;  

  reviewing and recommending any incentive compensation or equity plans, programs or other similar arrangements;  

  periodically reviewing and reassessing the adequacy of the